Cardiovascular endocrinology A New Era in Improving Cardiovascular Outcomes

Stay informed on news, research advances, and label updates. As our understanding and treatment of vascular disease continues to evolve, patients benefit.

Vitamin D Deficiency May Indicate Cardiovascular Disease in Overweight and Obese Children
April 4, 2017 | In overweight and obese children and adolescents, vitamin D deficiency is associated with early markers of cardiovascular disease, a new study reports. The research…

Patients with Heart Failure, Subclinical Hypothyroidism Have Worse Outcomes
April 2, 2017 | Patients with more severe heart failure have higher levels of the thyroid hormones TSH and T4 and lower T3 levels, and those with higher T4 levels…

People with Higher Thyroid Hormone Levels May be at Greater Risk for Atherosclerosis
April 1, 2017 | Middle-aged and elderly people with higher free thyroxine levels may be more likely to develop atherosclerotic diseases, new research from the Netherlands…

Take Heart: New Research Strengthens the Cardio/Endocrine Connection
February 2017 | According to the Endocrine Society’s Facts and Figures report on Cardiovascular & Lipids, cardiovascular disease is the number one cause of mortality in the U.S. Although the death rate…

In Concert: Treating Diabetes & Heart Disease
January 2017 | Cardiovascular disease (CVD) is the leading cause of death for men and women of most ethnicities in the U.S., and one of the main risk factors for CVD is diabetes…

Stressed Out: New Treatment Guidelines for Primary Aldosteronism
October 2016 | A new Endocrine Society Clinical Practice Guideline calls primary aldosteronism a major public health challenge. Research shows that an excessive level of aldosterone, far from being a rare…

John W. Funder Awarded Fondation IPSEN Endocrine Regulations Prize
September 2016 | Endocrine Society member John W. Funder, MD, PhD, of Prince Henry’s Institute in Victoria, Australia, today was awarded the Fondation PSEN Endocrine Regulations Prize for his work…

FCS Support Group Launched
September 2016 | A group of concerned patients and care providers for a rare disease have announced the formation of the first-ever organization dedicated to providing education and support for people…

Matters of the Heart: The Vital Link between the Cardiovascular and Endocrine Systems
February 2016 | While it’s well known that the endocrine system plays an important role on cardiovascular function, new research from around the world solidly demonstrates the numerous links between…

Updates in Cardiovascular Risk Reduction in Type 2 Diabetes: New Insights and Outcomes in Treatment Options
ENDO Satellite Symposium | 2.5 AMA PRA Category 1 Credits™ and ABIM MOC Part 2 points
Chair: Bernard Zinman, MD
Faculty: Naveed Sattar, PhD, FRCP; Hertzel C. Gerstein, MD; and Silvio E. Inzucchi, MD
Identify cardiovascular risk factors and develop strategies to reduce risks in patients with diabetes using new insights and outcomes data.

PCSK9 Inhibition: A Revolution in Cholesterol Therapy
ENDO Satellite Symposium | 2.0 AMA PRA Category 1 Credits™
Chair: Sergio Fazio, MD, PhD
Faculty: Ira J. Goldberg, MD; Kenneth R. Feingold, MD; and Evan A. Stein, MD, PhD
Keep up to date on management strategies amidst newer cholesterol-lowering therapies.

Creating Clarity for Very High Triglycerides Care
Online Course | 2.25 AMA PRA Category 1 Credits™
Faculty: Robert Eckel, MD; Michael Miller, MD; Harold Bays, MD; Sergio Fazio, MD, PhD; and Eliot Brinton, MD
Learn about the molecular underpinnings of disease and relationships to endocrinopathies using updated guidelines and case examples.

Primary Hyperaldosteronism
ENDO Session | No credit available
William F Young, Jr., MD, MSc
Review email consults in a computer-based CPC to learn practical approaches to diagnosing and treating hyperaldosteronism.

Heart Health Digital Toolkit
Patient Resource | No credit available
Reviewer: Robert M. Carey, MD
Check out interactive and downloadable resources and information for patients with questions about cardiovascular health and disease.

Endocrine Facts & Figures: Cardiovascular and Lipids
Research Resource | No credit available
Advisory Panel Chair: Robert A. Vigersky, MD
Updated epidemiological data and in-depth discussion on lipid disorders, cardiovascular disease, and endocrine-related risks with current citations and expert insights.

Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Endocrine Reviews | April 5, 2017
William F. Young, Jr., David A. Calhoun, Jacques W.M. Lenders, Michael Stowasser, Stephen C. Textor
Hypertension affects 28.6% of adults in United States. In most, hypertension is primary (essential or idiopathic), but a subgroup of approximately 15% has secondary hypertension…

The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
JCEM | October 6, 2016
Rebecca J. Brown, David Araujo-Vilar, Pik To Cheung, David Dunger, Abhimanyu Garg, Michelle Jack, Lucy Mungai, Elif A. Oral, Nivedita Patni, Kristina I. Rother, Julia von Schnurbein, Ekaterina Sorkina, Takara Stanley, Corinne Vigouroux, Martin Wabitsch, Rachel Williams and Tohru Yorifuji
Lipodystrophy syndromes are extremely rare disorders of deficient body fat associated with potentially serious metabolic complications, including diabetes, hypertriglyceridemia, and steatohepatitis. Due to their rarity…

Posttranslational Modifications of Lipid-Activated Nuclear Receptors: Focus on Metabolism
Endocrinology | December 07, 2016
Natalia Becares, Matthew C. Gage, and Inés Pineda-Torra
Posttranslational modifications (PTMs), or the covalent modification of a protein catalyzed by enzymes, increase the functional…

N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population
JCEM | July 11, 2016
Tore Hedbäck, Peter Almgren, Peter M. Nilsson and Olle Melander
Somatostatin inhibits a range of hormones, including GH, insulin, and glucagon, but little is known about its role in the development of cardiometabolic disease. Objective: The objective of the study…

A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients with Type 2 Diabetes
JCEM | June 14, 2016
Peter P. Swoboda, Adam K. McDiarmid, Bara Erhayiem, Philip Haaf, Ananth Kidambi, Graham J. Fent, Laura E. Dobson, Tarique A. Musa, Pankaj Garg, Graham R. Law, Mark T. Kearney, Julian H. Barth, Ramzi Ajjan, John P. Greenwood and Sven Plein
Silent myocardial infarction (MI) is a prevalent finding in patients with type 2 diabetes and is associated with significant mortality and morbidity. Late gadolinium enhancement (LGE) by…

Cardiovascular Risk in Women with Premature Ovarian Insufficiency Compared to Premenopausal Women at Middle Age
JCEM | June 14, 2016
Nadine M. P. Daan, Taulant Muka, Maria P. H. Koster, Jaenine E. Roeters van Lennep, Cornelis B. Lambalk, Joop S. E. Laven, Clemens G. K. M. Fauser, Cindy Meun, Yolanda B. de Rijke, Eric Boersma, Oscar H. Franco, Maryam Kavousi and Bart C. J. M. Fauser
A young age at menopause has been associated with increased cardiovascular disease (CVD) risk. Objective: To compare the cardiovascular risk profile between women with premature ovarian insufficiency…

Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN)
JCEM | June 13, 2016
Po-Yin Chang, Ellen B. Gold, Jane A. Cauley, Wesley O. Johnson, Carrie Karvonen-Gutierrez, Elizabeth A. Jackson, Kristine M. Ruppert and Jennifer S. Lee
Unfavorable lipid levels contribute to cardiovascular disease and may also harm bone health. Our objective was to investigate relationships between fasting plasma lipid levels and incident fracture…

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis
JCEM | May 24, 2016
Anne Langsted, Børge G. Nordestgaard, Marianne Benn, Anne Tybjærg-Hansen and Pia R. Kamstrup
Novel, low-density lipoprotein (LDL) cholesterol-lowering proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors also lower lipoprotein(a) levels, but the effect on aortic valve stenosis and myocardial infarction…

Cardiac Death Risk in Relation to the Age at Initiation or the Progestin Component of Hormone Therapies
JCEM | May 12, 2016
Hanna Savolainen-Peltonen, Pauliina Tuomikoski, Pasi Korhonen, Fabian Hoti, Pia Vattulainen, Mika Gissler, Olavi Ylikorkala and Tomi S. Mikkola
The “window of opportunity hypothesis” refers to data indicating that conjugated equine estrogen alone or in combination with medroxyprogesterone acetate, if initiated before 60 years of age…

Elevated Glucose Oxidation, Reduced Insulin Secretion, and a Fatty Heart May Be Protective Adaptions in Ischemic CAD
JCEM | April 5, 2016
J. C. Hannukainen, R. Lautamäki, A. Mari, J. P. Pärkkä, M. Bucci, M. A. Guzzardi, S. Kajander, T. Tuokkola, J. Knuuti and P. Iozzo
Insulin resistance, β-cell dysfunction, and ectopic fat deposition have been implicated in the pathogenesis of coronary artery disease (CAD) and type 2 diabetes, which is common in CAD…

Circulating Sex Steroids and Vascular Calcification in Community-Dwelling Men: The Framingham Heart Study
JCEM | March 1, 2016
Thomas G. Travison, Christopher J. O'Donnell, Shalender Bhasin, Joseph M. Massaro, Udo Hoffmann, Ramachandran S. Vasan, Ralph B. D'Agostino Sr. and Shehzad Basaria
The relationship between sex steroids and atherosclerosis is poorly understood. To describe the association of serum total T (TT), calculated free T (cFT), estrone (E1), estradiol (E2), and SHBG to…

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment
JCEM | March 2, 2016
John W. Funder, Robert M. Carey, Franco Mantero, M. Hassan Murad, Martin Reincke, Hirotaka Shibata, Michael Stowasser, and William F. Young Jr.
For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions…

Evaluation and Treatment of Hypertriglyceridemia
JCEM | July 2, 2013
Lars Berglund, John D. Brunzell, Anne C. Goldberg, Ira J. Goldberg, Frank Sacks, Mohammad Hassan Murad, and Anton F. H. Stalenhoef
The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150–999 mg/dl) be diagnosed…

Primary Prevention of Cardiovascular Disease and Type 2 Diabetes in Patients at Metabolic Risk
JCEM | January 14, 2009
James L. Rosenzweig, Ele Ferrannini, Scott M. Grundy, Steven M. Haffner, Robert J. Heine, Edward S. Horton, and Ryuzo Kawamori
Healthcare providers should incorporate into their practice concrete measures to reduce the risk of developing CVD and T2DM. These include the regular screening and identification…

National Lipid Association Scientific Sessions 2017
Dates: May 18 - 21, 2017
Location: Philadelphia, Pennsylvania, United States
Sponsor: National Lipid Association

Popular Resources